**EMBECTA CORP.**
**CHARTER OF THE**
**TECHNOLOGY, QUALITY AND REGULATORY COMMITTEE**
*Effective April 1, 2022*
*Last Amended August 6, 2025*

## Purpose

The Technology, Quality and Regulatory Committee (the "Committee") is created by the Board of Directors of the Company to assist the Board in overseeing the quality and competitiveness of the Company's product portfolio and manufacturing capabilities, including new product development and innovation, research and development ("R&D") activities, quality systems, and regulatory compliance matters.

## Membership

The Committee shall consist of at least three members of the Board of Directors. Committee members need not be "independent" under the Company's Corporate Governance Principles and the independence requirements of The Nasdaq Stock Market LLC. The Corporate Governance and Nominating Committee shall recommend nominees for appointment to the Committee annually and as vacancies or newly created positions occur. Committee members shall be appointed by the Board of Directors and may be removed by the Board of Directors at any time. The Corporate Governance and Nominating Committee shall recommend to the Board of Directors, and the Board of Directors shall designate, the Chair of the Committee.

## Authority and Responsibility

In addition to any other responsibilities that may be assigned to it from time-to-time by the Board of Directors, the Committee is responsible for oversight of matters relating to the quality and competitiveness of the Company's product portfolio and manufacturing capabilities, including new product development and innovation, R&D activities, quality systems, and regulatory compliance matters. Such oversight shall include the following:

*Innovation and New Product Development*

- Reviewing with management the Company's key new product development programs, governance systems, and practices in order to improve the Company's innovation programs, product development, and launch effectiveness, and to increase R&D productivity.

- Such review may include assessing:

    - alignment between Company's innovation and product development pipeline and its strategy and growth objectives; and

    - appropriateness of resources and budget to support innovation, new product development, and life cycle management of the Company's products.

- Monitoring the Company's progress against program objectives, including revenue, efficiency, and product development targets.

- Reviewing the Company's organizational capabilities and systems in light of program objectives, including without limitation, in the areas of R&D, regulatory, manufacturing, operations, quality, distribution, and clinical and medical affairs.

- Periodically reviewing the Company's innovation, new product development, and lifecycle management activities in light of critical developments in its core markets, including potentially disruptive trends, opportunities, risks, and gaps in technological, scientific, environmental, medical, or external market conditions.

- Periodically reviewing the Company's intellectual property portfolio and strategy.

*Manufacturing Capabilities*

- Reviewing the Company's manufacturing capabilities, including manufacturing capacity, cost improvements, and other key metrics as it relates to the Company's core business, strategy, and growth objectives.

*Quality*

- Discussing the Company's quality metrics as regularly reported by management, including review of any significant product quality issues.

- Periodically reviewing the Company's sustaining engineering efforts and progress.

*Regulatory*

- Reviewing the Company's global regulatory efforts, including, as applicable, ongoing compliance with regulatory changes.

*Risk Management, Supply Chain and Product Cybersecurity*

- Reviewing stockholder proposals that relate to matters within the scope of the Committee's responsibilities in order to review and make recommendations to the Board of Directors regarding such proposals.

- As part of an overall risk management assessment, periodically reviewing and evaluating:

    - the combined capabilities of the Company's R&D, quality assurance, regulatory affairs, manufacturing, operations, distribution, and clinical and

medical affairs functions; and

- technological aspects of new and existing products and services as they relate to quality, safety, and cybersecurity.

- Site-based visits, when appropriate, for a hands-on perspective with respect to any of the above.

**Reporting to the Board of Directors**

The Committee shall report to the Board of Directors periodically on matters reviewed by the Committee, and any other matter that the Committee deems appropriate or is requested to be included by the Board of Directors.

At least annually, the Committee shall evaluate its own performance and report to the Board of Directors on such evaluation.

The Committee shall, at least annually, review and assess the adequacy of this Charter and recommend any proposed changes to the Corporate Governance and Nominating Committee.

**Procedures**

The Committee shall meet as often as it determines is appropriate to carry out its responsibilities under this Charter. The Chair of the Committee, in consultation with the other Committee members and management, shall determine the frequency and length of Committee meetings, and shall determine meeting agendas consistent with this Charter.

The Committee is authorized to retain legal and any other advisors as it determines necessary to carry out its duties, and may request any officer or employee of the Company, or the Company's outside counsel, to meet with any members of, or advisors to, the Committee.

The Company shall provide for appropriate funding, as determined by the Committee, for (i) the costs of any legal or other advisors retained by the Committee and (ii) the administrative expenses of the Committee that are necessary or appropriate to carrying out its duties.

The Committee may delegate its authority to subcommittees or to the Chair of the Committee when it deems it appropriate and in the best interests of the Company.